Paper Details

  1. Home
  2. Paper Details

A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.

Author: AkınMustafa, KurhanFaruk

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This systematic review evaluates the use of pimavanserin, an atypical antipsychotic, in treating psychosis in Alzheimer's disease (ADP). Pimavanserin has demonstrated effectiveness in reducing delusions and hallucinations in ADP, with a unique mechanism of action that targets 5-HT2A receptors. This suggests that pimavanserin may be a valuable treatment option for ADP, particularly in cases resistant to conventional therapies.
Paper Details　
Original Abstract of the Article :
Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1567205020666230825124922

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Alzheimer's Disease: Exploring the Potential of Pimavanserin for Psychosis

The [fight against Alzheimer's disease (AD)] is a relentless journey through a vast and unforgiving desert, where [treating the associated psychosis] is a significant challenge. This study explores the [potential of pimavanserin], an [atypical antipsychotic], for [treating psychosis in patients with AD]. The researchers review the [current literature] on [pimavanserin's use in ADP] and highlight its [unique mechanism of action] and its [promising results] in [clinical trials].

A Glimmer of Hope in the Desert: Pimavanserin Shows Promise for Alzheimer's Disease Psychosis

The study suggests that [pimavanserin] may offer a [potential treatment option] for [ADP], with a [unique mechanism of action] that [targets specific receptors] involved in [psychotic symptoms]. This finding could be [transformative] for [patients with AD and psychosis], providing a [new avenue for relief] from these [debilitating symptoms].

Navigating the Desert of Alzheimer's Disease: Understanding the Importance of Treating Psychosis

The study underscores the [importance of addressing] the [psychotic symptoms] associated with [AD], as they can [significantly impact] the [quality of life] for [patients and their caregivers]. This emphasizes the [need for effective treatments] to [improve symptom management] and [enhance the overall well-being] of [individuals with AD].

Dr.Camel's Conclusion

The desert of Alzheimer's disease is a harsh and unforgiving landscape, but the potential of pimavanserin for treating psychosis offers a new oasis of hope. This atypical antipsychotic could provide relief for patients struggling with the debilitating symptoms of AD psychosis, improving their quality of life and offering a path towards a brighter future.

Date :
  1. Date Completed 2023-11-23
  2. Date Revised 2023-11-23
Further Info :

Pubmed ID

37641988

DOI: Digital Object Identifier

10.2174/1567205020666230825124922

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.